Cipla's Bengaluru Plant Gets USFDA VAI Status

9 Feb 2025 , 11:20 PM

Cipla Ltd’s Virgonagar manufacturing facility, Bengaluru, has received VAI status from USFDA. The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

The USFDA has conducted routine cGMP inspection at the facility in the period between November 7 through November 13, 2024. VAI status is better than OAI status, as it may invite regulatory consequences.

Cipla recently announced robust December quarter results. Revenue for Q3 FY25 grew 7% YoY to ₹7,073 crore, showing steady business growth. Net profit rose 49% YoY to ₹1,570 crore, led by operational efficiencies. EBITDA rose 14% YoY to ₹1,989 crore, showing strong profit performance. EBIDTA margin had improved by 200 basis points at 28% compared with the prior year’s 26%. For nine months FY25, EBITDA margin was 26.9%, well above the company’s guided range of 24.5% and 25.5%. Domestic sales totaled US$226 million and registered a decline of 2% YoY.

Shares of Cipla closed at ₹1470 on Friday which is a 0.11% dip than the previous close. The stock has gained a total of 2.10% in the last one year, and a total of 1.22% dip in the last one month.